<i>APOL1</i> renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial.

In the subgroup without CKD at baseline, a nonsignificant trend was observed for the prespecified end-point of a 30% reduction in eGFR (measured twice ≥90 days apart) to an eGFR < 60 ml/min per 1.73 m 2 , initiation of dialysis, or kidney transplantation (HR = 1.64, 95% CI = 0.85−2.93, P = 0.114 recessive model), but not for incident proteinuria.

also in 5,406 other papers